Streetbeat News

TALS

Talaris Therapeutics Inc

Employees

125

Industry

Research and Development in Biotechnology

talaris therapeutics is a late-clinical stage biotechnology company based in boston, ma and louisville, ky. talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. the company was founded on technology discovered and developed by dr. suzanne ildstad and operates its own cell processing facility in louisville. talaris is backed by leading life sciences investors blackstone life sciences, longitude capital and qiming venture partners usa.

Open

2.78

Mkt cap

116M

Volume

303K

High

2.79

P/E Ratio

-1.56

52-wk high

3.29

Low

2.69

Div yield

N/A

52-wk low

0.89

Several stocks are experiencing significant pre-market movements. Biocept, Inc. (BIOC) surged 91.8% after filing for Chapter 7 bankruptcy. Shift Technologies, Inc. (SFT) rose 74.4% after announcing plans to file for Chapter 11 bankruptcy. Connexa Sports Technologies Inc. (CNXA) gained 45% and RVL Pharmaceuticals plc (RVLP) climbed 41.2% after receiving a delisting notice. Talaris Therapeutics, Inc. (TALS) jumped 8.2% after announcing stockholder approval of a merger with Tourmaline Bio and a 1-for-10 reverse stock split.

Portfolio Pulse from Lisa Levin

October 18, 2023 | 12:19 pm

Talaris Therapeutics, Inc. (TALS) has announced a 1-for-10 reverse stock split of its common stock. The reverse stock split will reduce the number of shares outstanding and is expected to increase the market price per share.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 9:51 pm

Talaris Therapeutics has announced that its stockholders have approved the merger with Tourmaline Bio. The merger is expected to be completed soon.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 9:49 pm

The correct ticker for Talaris Therapeutics is 'TALS', not 'TAL'.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 8:53 pm

Talaris Therapeutics has received a notice of material breach from Immunofree, alleging that the company breached a provision of APA June 28. On October 6, Talaris and Immunofree executed a binding settlement agreement, with Talaris agreeing to pay Immunofree $4M.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 8:50 pm

Several healthcare stocks experienced significant movement in Friday's after-market session. ContraFect, Exagen, Pasithea Therapeutics, Talaris Therapeutics, Renalytix, and GRI Bio saw their stocks rise, while Addex Therapeutics, Dyadic International, Sunshine Biopharma, Senti Biosciences, First Wave BioPharma, and Salarius Pharmaceuticals experienced a decline.

Portfolio Pulse from Benzinga Insights

October 06, 2023 | 9:31 pm

New York Blood Center Enterprises (NYBCe) has acquired commercial-scale cell and gene therapy development and manufacturing facilities from Talaris Therapeutics, Inc. (NASDAQ:TALS). The acquisition includes facilities in Houston, Texas and Louisville, Kentucky, as well as certain technologies and equipment. The deal will enhance NYBCe's cell and gene therapy development and manufacturing capabilities, and accelerate the delivery of a fully integrated vein-to-vein cell and gene therapy solution for the US.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 12:39 pm

ImmunoFree, Inc. has acquired the rights to FCR001, a cellular therapy product, and the sponsorship of the FREEDOM-1 Study from Talaris Therapeutics (TALS). ImmunoFree will now oversee all remaining close-out activities and the shutdown of the remaining active FREEDOM-1 phase 3 clinical sites. The company plans to commence a new clinical trial with modifications to the protocol to improve patient outcomes.

Portfolio Pulse from Happy Mohamed

August 14, 2023 | 5:12 pm

In Wednesday's pre-market session, several health care stocks showed significant movement. Tilray Brands, Talaris Therapeutics, Aspira Womens Health, cbdMD, G Medical Innovations, and Erasca saw increases, while INVO Bioscience, XTL Biopharmaceuticals, Fresh Tracks Therapeutics, Armata Pharmaceuticals, PaxMedica, and BrainsWay experienced decreases.

Portfolio Pulse from Benzinga Insights

July 26, 2023 | 1:06 pm

U.S. stocks traded mostly higher, with NASDAQ Composite gaining around 100 points. Crude oil prices dropped over 4%. Consumer discretionary shares rose 1.1%, while real estate shares dipped by 1.3%. Root, Inc. shares shot up 39% after receiving a takeover bid. Aeglea BioTherapeutics acquired Spyre Therapeutics and raised $210 million in gross proceeds.

Portfolio Pulse from Lisa Levin

June 22, 2023 | 6:55 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.